Rathbones Group PLC Grows Stake in Guardant Health, Inc. $GH

Rathbones Group PLC raised its stake in Guardant Health, Inc. (NASDAQ:GH) by 2.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 205,113 shares of the company’s stock after acquiring an additional 5,025 shares during the quarter. Rathbones Group PLC owned approximately 0.16% of Guardant Health worth $20,950,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in GH. AQR Capital Management LLC boosted its stake in Guardant Health by 56.5% in the first quarter. AQR Capital Management LLC now owns 71,534 shares of the company’s stock valued at $3,012,000 after acquiring an additional 25,831 shares during the last quarter. Empowered Funds LLC purchased a new position in Guardant Health in the first quarter valued at about $274,000. Sei Investments Co. boosted its stake in Guardant Health by 15.8% in the second quarter. Sei Investments Co. now owns 77,308 shares of the company’s stock valued at $4,023,000 after acquiring an additional 10,538 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Guardant Health by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 632,630 shares of the company’s stock valued at $32,922,000 after buying an additional 54,284 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Guardant Health by 56.4% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 111,445 shares of the company’s stock valued at $5,800,000 after buying an additional 40,209 shares in the last quarter. 92.60% of the stock is currently owned by hedge funds and other institutional investors.

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $118.01 on Friday. The company’s fifty day moving average price is $90.53 and its 200-day moving average price is $98.79. The firm has a market capitalization of $15.65 billion, a price-to-earnings ratio of -34.81 and a beta of 1.48. Guardant Health, Inc. has a one year low of $36.36 and a one year high of $121.01.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.07). The firm had revenue of $281.27 million for the quarter, compared to analysts’ expectations of $269.74 million. Guardant Health’s revenue was up 39.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.62) earnings per share. As a group, equities research analysts expect that Guardant Health, Inc. will post -2.92 EPS for the current year.

Insider Transactions at Guardant Health

In other news, CFO Michael Brian Bell sold 3,000 shares of the stock in a transaction on Monday, March 16th. The shares were sold at an average price of $87.04, for a total value of $261,120.00. Following the transaction, the chief financial officer owned 43,601 shares of the company’s stock, valued at $3,795,031.04. This represents a 6.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Medina Manuel Hidalgo sold 1,300 shares of the stock in a transaction on Friday, March 6th. The stock was sold at an average price of $91.54, for a total transaction of $119,002.00. Following the completion of the transaction, the director directly owned 1,193 shares in the company, valued at $109,207.22. The trade was a 52.15% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 58,712 shares of company stock worth $5,802,899. Company insiders own 5.60% of the company’s stock.

Wall Street Analysts Forecast Growth

GH has been the topic of a number of recent research reports. Piper Sandler set a $127.00 price target on shares of Guardant Health in a research note on Thursday. Guggenheim upped their price target on shares of Guardant Health from $115.00 to $135.00 and gave the company a “buy” rating in a research note on Monday, January 26th. BTIG Research upped their price target on shares of Guardant Health from $140.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, February 20th. Barclays upped their price target on shares of Guardant Health from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Finally, Leerink Partners upped their price target on shares of Guardant Health from $170.00 to $180.00 and gave the company an “outperform” rating in a research note on Friday, February 20th. Nineteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $129.00.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.